HOUSE, PA — Johnson & Johnson has announced promising results from its Phase 3b APEX trial for TREMFYA® (guselkumab), ...

US-based pharmaceutical company Johnson & Johnson (J&J) has reported positive results from a Phase IIIb trial of its ...

Johnson & Johnson's Phase 3b APEX study shows Tremfya reduces symptoms and structural damage in psoriatic arthritis patients ...

Johnson & Johnson announces positive results from phase 3b APEX study of Tremfya to treat adults living with active psoriatic arthritis: Spring House, Pennsylvania Monday, April 7 ...

highlighting the antibody-based drug’s efficacy as a first-line option for patients with active psoriatic arthritis ((PsA)). JNJ said that Tremfya, which is already approved in the U.S. for PsA ...

Johnson & Johnson (NYSE: JNJ) announced today that its drug TREMFYA (guselkumab) has met the primary and major secondary endpoints in a Phase 3b APEX study for treating active psoriatic arthritis ...

Johnson & Johnson announced that the Tremfya Phase 3b APEX study achieved both its primary endpoint of reducing signs and symptoms and its ...

Psoriatic arthritis is a combination of psoriasis and arthritis symptoms. You may have skin and nail changes, joint pain and ...

Psoriatic arthritis represents a complex intersection of immune dysfunction where inflammation targets both skin and joints, ...

Johnson & Johnson (NYSE:JNJ) on Friday announced topline results from Phase 3b APEX study of Tremfya (guselkumab) in patients with active psoriatic arthritis (PsA) who are biologic naïve and have ...

SPRING HOUSE, Pa. - Johnson & Johnson (NYSE: JNJ) announced today that its drug TREMFYA (guselkumab) has met the primary and major secondary endpoints in a Phase 3b APEX study for treating active ...